ArticleMetabolites2019
Metabolic Fingerprint of Chronic Obstructive Lung Diseases: A New Diagnostic Perspective.
Article in Metabolites, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Metabolite Alterations in Autoimmune Diseases: A Systematic Review of Metabolomics Studies.Metabolites · 2023Review
- Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis.Progress in biomaterials · 2022Review
- Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation.Cancer cell international · 2022Review
- Metabolomic Analysis of Plasma from Breast Cancer Patients Using Ultra-High-Performance Liquid Chromatography Coupled with Mass Spectrometry: An Untargeted Study.Metabolites · 2022Article
- Reversal of brain aging by targeting telomerase: A nutraceutical approach.International journal of molecular medicine · 2021Article
- The snapshot of metabolic health in evaluating micronutrient status, the risk of infection and clinical outcome of COVID-19.Clinical nutrition ESPEN · 2021Review
- A Clinical Trial for the Identification of Metabolic Biomarkers in Hashimoto's Thyroiditis and in Psoriasis: Study Protocol.Pathophysiology : the official journal of the International Society for Pathophysiology · 2021Article
- Application of Metabolomics in Pediatric Asthma: Prediction, Diagnosis and Personalized Treatment.Metabolites · 2021Review
- Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits.Oxidative medicine and cellular longevity · 2021Review
- An original biomarker for the risk of developing cardiovascular diseases and their complications: Telomere length.Toxicology reports · 2021Article
- Prediction of Autoimmune Diseases by Targeted Metabolomic Assay of Urinary Organic Acids.Metabolites · 2020Article
- Internet of Medical Things: An Effective and Fully Automatic IoT Approach Using Deep Learning and Fine-Tuning to Lung CT Segmentation.Sensors (Basel, Switzerland) · 2020Article
- Alterations in telomere length and mitochondrial DNA copy number in human lymphocytes on short-term exposure to moderate hypoxia.Toxicology reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive lung disease (COLD) is a group of airway diseases, previously known as emphysema and chronic bronchitis. The heterogeneity of COLD does not allow early diagnosis and leads to increased morbidity and mortality. The increasing number of COLD incidences stresses the need for precision medicine approaches that are specific to the patient. Metabolomics is an emerging technology that allows for the discrimination of metabolic changes in the cell as a result of environmental factors and specific genetic background. Thus, quantification of metabolites in human biofluids can provide insights into the metabolic state of the individual in real time and unravel the presence of, or predisposition to, a disease. In this article, the advantages of and potential barriers to putting metabolomics into clinical practice for COLD are discussed. Today, metabolomics is mostly lab-based, and research studies with novel COLD-specific biomarkers are continuously being published. Several obstacles in the research and the market field hamper the translation of these data into clinical practice. However, technological and computational advances will facilitate the clinical interpretation of data and provide healthcare professionals with the tools to prevent, diagnose, and treat COLD with precision in the coming decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.